Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1200/JCO.2016.70.8891 http://scihub22266oqcxt.onion/10.1200/JCO.2016.70.8891 C5652384!5652384 !28297622     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=28297622 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\28297622 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       J+Clin+Oncol 2017 ; 35 (9 ): 1011-1017 Nephropedia Template TP {{tp|p=28297622 |t=2017. Clinical Trials in the Genomic Era |pdf=|usr=}}{{28297622 }} gab.com Text Clinical Trials in the Genomic Era JO: J Clin Oncol http://www.kidney.de/pget.php?&tw=1&pmid=28297622 #FOAvip Personalization of therapy to target specific molecular pathways has been placed in the forefront of cancer research. Initial reports from clinical trials designed to select patients for appropriate treatment on the basis of tumor characteristics not only have generated considerable excitement but also have identified several challenges. These challenges include the overcoming of regulatory and logistic difficulties, identification of the best selection biomarkers and diagnostic platforms that can be applied in the clinical setting, definition of relevant outcomes in small preselected patient populations, and the design of methods that facilitate rapid enrollment and interpretation of clinical trials by aggregating data across histologically diverse malignancies with common genetic alterations. Furthermore, because our knowledge of the functional consequences of many genetic alterations lags, investigators and sponsors struggle with choosing between ideal clinical trial designs and more practical ones. These challenges are amplified when more than one biomarker is used to select patients for a combination of targeted agents. This review summarizes the current status and challenges of clinical trials in the genomic era and proposes ways to address these challenges. Twit Text FOAVip Clinical Trials in the Genomic Era ????J Clin Oncol http://www.kidney.de/pget.php?&tw=1&pmid=28297622 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28297622 #FOAvip English Wikipedia <ref>{{Cite pmid|28297622 }}</ref> Clinical Trials in the Genomic Era #MMPMID28297622 Joffe E ; Iasonos A ; Younes A J Clin Oncol 2017[Mar]; 35 (9 ): 1011-1017 PMID28297622 show ga Personalization of therapy to target specific molecular pathways has been placed in the forefront of cancer research. Initial reports from clinical trials designed to select patients for appropriate treatment on the basis of tumor characteristics not only have generated considerable excitement but also have identified several challenges. These challenges include the overcoming of regulatory and logistic difficulties, identification of the best selection biomarkers and diagnostic platforms that can be applied in the clinical setting, definition of relevant outcomes in small preselected patient populations, and the design of methods that facilitate rapid enrollment and interpretation of clinical trials by aggregating data across histologically diverse malignancies with common genetic alterations. Furthermore, because our knowledge of the functional consequences of many genetic alterations lags, investigators and sponsors struggle with choosing between ideal clinical trial designs and more practical ones. These challenges are amplified when more than one biomarker is used to select patients for a combination of targeted agents. This review summarizes the current status and challenges of clinical trials in the genomic era and proposes ways to address these challenges. |Clinical Trials as Topic/*methods [MESH] |Genomics/*methods [MESH] |Humans [MESH] |Molecular Targeted Therapy [MESH]Clinical Trials in the Genomic Era (epmc).pdf DeepDyve Pubget Overpricing